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Introduction
Activation of the signaling pathway mediated by gly-
coprotein(gp)-130 by interleukin-6 (IL-6) and its solu-
ble receptor (sIL-6R) was regarded as a pivotal mech-
anism for the regulation of osteoclastogenesis [1,2].
Nevertheless, in IL-6 knockout (IL6KO) mice no spe-
cific changes in bone structure were found [3,4].
Moreover, in gp-130 deficient mice the amount of
osteoclasts was highly elevated [5]. These data suggest
that IL-6 does not influence resorption and normal
bone turnover. However, IL6KO mice were protected
against increased bone resorption after acute estrogen
depletion owing to ovariectomy [6]. IL-6 was also
shown to be involved in other processes associated
with accelerated bone turnover such as Paget disease,
multiple myeloma, rheumatoid arthritis and renal
osteodystrophy [7-10]. Moreover selective inhibitor of
IL-6 activity has been documented to suppress bone
mass reduction [11]. However, recently published
results of the study on IL6KO mice have demonstrat-
ed that in hyperparathyroidism IL-6 is not required for
the osteoclast formation and bone loss [12]. Lately we
have observed highly elevated osteocalcin levels in
IL6KO mice in thyrotoxicosis, suggesting crucial role
of IL-6 in bone formation in hyperthyroidism [13].
Data on role of IL-6 in bone turnover in hypothy-
roidism are lacking. 
Thus, the aim of the present study was to estimate
serum markers of bone turnover: osteoclast-derived
tartrate-resistant acid phosphatase form 5a (TRACP
5b) reflecting resorption, and osteocalcin as a marker
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Abstract: Interleukin-6 (IL-6) has been shown to be involved in the pathogenesis of several bone diseases characterized by
an imbalance between bone resorption and formation. The aim of the study was to estimate serum markers of bone turnover:
osteoclast-derived tartrate-resistant acid phosphatase form 5a (TRACP 5b) and osteocalcin in IL-6-deficient mice to assess
the role of IL-6 in bone metabolism in hypothyroidism in mice. C57BL/6J (wild-type; WT) and C57BL/6JIL6-/-Kopf (IL-6
knock-out; IL6KO) mice randomly divided into 4 groups with 10 in each one: 1/ WT mice in hypothyroidism (WT-ht), 2/
WT controls, 3/ IL6KO mice with hypothyroidism (IL6KO-ht) and 4/ IL6KO controls. Experimental model of hypothy-
roidism was induced by intraperitoneal injection of propylthiouracyl. The serum levels of TRACP 5b and osteocalcin were
determined by ELISA. Serum concentrations of TRACP 5b (median and interquartile ranges) were significantly decreased
in both groups of mice with hypothyroidism: WT (3.2 (2.5-4.7) U/l) and IL6KO (2.6 (1.8-3.5) U/l) as compared to the
respective controls. Similarly, serum osteocalcin levels were significantly reduced in both groups of mice in experimental
hypothyroidism: WT (25.8 (23.0-28.2) ng/ml) and IL6KO (21.5(19.0-24.6) ng/ml) in comparison to the respective controls.
There were no significant differences in bone turnover markers between IL6KO and WT mice both in hypothyroid and con-
trol animals. The results of the present study suggest that IL-6 does not play an important role in bone turnover in both euthy-
roid and hypothyroid mice.
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of bone formation in IL-6-deficient mice to assess the
role of IL-6 in the bone turnover in hypothyroidism. 
Materials and Methods
Experimental animals. The study was performed on forty, 14-15
weeks old, female mice: C57BL/6J (wild-type; WT) and
C57BL/6JIL6-/-Kopf (IL6KO) weighing 18-22 g at the beginning of
the experiment. The IL6KO mice used in this study were obtained
from the Department of Cardiology and Angiology of Medical
School in Hannover. All animals had free access to standard gran-
ulated diet and drinking water. The animals were housed in plastic
cages at 22.1°C and constant humidity, with a 12/12 light/dark
cycle, beginning at 7 am. 
The mice were randomly divided into 4 groups with 10 mice in
each one: 1/ WT mice in hypothyroidism (WT-ht), 2/ WT controls
(WT-ctrl), 3/ IL6KO mice in hypothyroidism (IL6KO-ht) and 4/
IL6KO controls. Experimental model of hypothyroidism was
induced by intraperitoneal injection of propylthiouracyl at the dose
of 60 μg/kg daily over 21 days. Control mice were injected vehicle
under the same experimental conditions.
Genotyping.  Genomic DNA for IL-6 genotyping was isolated from
mouse tails using "Genomic mini" kit (A&A Biotechnology, Gdansk,
Poland) according to the enclosed protocol. PCR was performed
using DNA polymerase Taq "Marathon" (A&A Biotechnology,
Gdansk, Poland) and custom made primers (F 5'-AAGTGCATC
ATCGTTGTTCATAC-3'; R 5'-CCATCCAGTTGCCTTCTTG-3').
Twenty nine PCR cycles were performed under following condi-
tions: 94°C 5 seconds, 94°C 20 seconds, 55°C 30 seconds, 72°C 2
min 50 seconds, 72°C 7 seconds, 10°C at the end of the procedure.
Then DNA was separated by electrophoresis on the 1% agarose gel
with ethidium bromide. 
Thyroid tissues. To verify an animal model of hypothyroidism mice
were thyreoidectomized. Both thyroid lobes were fixed in Bouin's
fluid for 24 hours in temperature of +4°C and embedded in paraffin
in a routine procedure. The specimens were cut into 5 μm slices and
stained by haematoxylin-eosin. The histological preparations were
subjected to analysis, using Olympus Bx50 microscope.
Osteodensitometry. Bone mineral density (BMD) was examined
in a-p position by the dual X-ray absorptiometry using Lunar DPX
densitometer (Lunar Corporation, Madison, WI, USA) with small
animal software. BMD measurements were performed by the same
experienced operator. The densitometer was calibrated everyday
with a standard phantom specimen. The following sites were
examined: the total body, tibia, trochanter and vertebrae L2-L4.
BMD results were obtained in absolute values (mg/cm2). 
Blood specimens. At the end of the experiment, the animals were
anaesthetized with ketamine (100 mg/kg) and xylazine-HCL (10
mg/kg), their abdomen was opened by midline incision and the
blood was taken from the abdominal aorta of each mouse for meas-
urement of serum concentrations of osteoclast-derived tartrate-
resistant acid phosphatase form 5a (TRACP 5b), osteocalcin and
creatinine. The blood was collected to polypropylene tubes without
anticoagulant and was incubated in room temperature until the clot
was formed and then centrifuged (2500 × g, 15 minutes). The
supernatant (serum) was removed and stored at -70°C until a con-
sequtive analysis. The serum levels of TRACP 5b and osteocalcin
were determined by enzyme-linked immunosorbent assay com-
mercial kits: TRACP 5b (MouseTRAP Assay, SBA Sciences,
Turku, Finland; sensitivity 0.1 U/l; intra-assay precision 6.5%;
inter-assay variation 8%) and osteocalcin (Mouse Osteocalcin EIA
kit, Biomedical Technologies Inc., Stoughton, USA; sensitivity 1
ng/ml; intra-assay precision 6%; inter-assay variation 8%). Serum
creatinine concentration was measured by autoanalyzer using stan-
dard laboratory methods.
Statistical analysis. The statistical significance was estimated by
Mann-Whitney U-test. To evaluate relationships between variables
Spearman's test was performed using Statistica 6.0 for Windows
XP (StaSoft, Tulsa, USA).
Ethical issues. All procedures were performed in compliance with
the European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the Local Ethics Com-
mittee in Bialystok.
Results
IL-6 genotyping
Material from wild-type animals yielded DNA frag-
ments with size ca. 900 bp, whereas DNA fragments
from IL6KO animals contained also a fragment of
neomycin cassette and were size about 1400 bp (Fig. 1).
Thyroid specimens
The efficacy of the animal model of hypothyroidism
has been confirmed by the histological picture of thy-
roid glands. The thyroids had a follicular, encapsulat-
ed structure in the control and experimental mice. The
differences between the central and peripheral follicles
in thyroids obtained from both IL6KO and WT control
mice were observed. The central follicles had a small-
er diameter, the colloid was less dense, and the follic-
ular epithelium was higher, whereas the peripheral fol-
licles were larger, delimited by flat cuboid epithelium
and homogenous, intensely stained colloid (Fig. 2A
and 2B). Examination of thyroid sections of IL6KO
and WT animals treated with propylthiouracyl pointed
to thyroid function blockade with predominance of
microfollicular hyperplasia with poor in colloid hyper-
plastic follicles of irregular shape. (Fig. 2C and 2D).
Osteodensitometry
BMD values (in mg/cm2) are shown in Table 1.  We
have not found any significant differences between
hypothyroid an control WT and IL6KO mice. 
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Fig. 1. IL-6 Genotyping of wild-type and IL6KO animals. DNA
electrophoresis on agarose gel.  Lane 1- DNA ladder, lanes 2 and
3- wild-type (C57BL/6J) animals, lane 4 to 6- C57BL/6JIL6-/-Kopf
mice.
Bone turnover serum markers
Moreover, significantly diminished values of TRACP
5b and osteocalcin as markers of bone turnover in
propylthiouracyl injected mice as compared to relative
controls may also serve as the confirmation of efficacy
of the animal model of hypothyroidism. Serum con-
centrations of TRACP 5b (median and interquartile
ranges) were significantly decreased in both groups of
mice with hypothyrosis (Fig. 3): WT (3.2 (2.5-4.7)
U/l) and IL6KO (2.6 (1.8-3.5) U/l) as compared to the
respective controls:  WT (8.4 (6.4-10.5) U/l) and
IL6KO (8.0 (5.0-9.8) U/l).  
Also, as can be seen in Fig.4, serum osteocalcin
concentrations (median and interquartile ranges) were
significantly diminished in both groups of mice in
experimental hypothyroidism: WT (25.8 (23.0-28.2)
ng/ml) and IL6KO (21.5(19.0-24.6) ng/ml) as com-
pared to the respective controls: WT (32.5 (27.6-37.3)
ng/ml) and IL6KO (30.5 (26.3-42.5) ng/ml). 
There were no significant differences between cre-
atinine serum concentrations (median and interquartile
ranges) in studied groups of mice with hypothy-
roidism: WT (0.17 (0.12-0.22) mg/dl) and IL6KO
(0.18 (0.12-0.25) mg/dl) as compared to the respective
controls:  WT (0.17 (0.12-0.23) mg/dl) and IL6KO
(0.20 (0.13-0.28) mg/dl).  
Discussion
The exact mechanism by which thyroid hormones reg-
ulate osteoblasts and osteoclasts function at a cellular
level remains unclear. Osteoblasts were documented to
synthesize thyroid receptors [14]. The presence of
osteoblasts seems to be a necessary condition for
osteoclasts to resorp bone in response to triiodotyro-
nine [15]. Triiodotyronine was reported to stimulate
389IL-6 in bone turnover in hypothyroid mice
Fig. 2. Light micrograph of thyroid gland (magnitude × 400.000): (A) C57BL/6J, (B) C57BL/6JIL6-/-Kopf, (C) C57BL/6J treated with
propylthiouracyl, (D) C57BL/6JIL6-/-Kopf treated with propylthiouracyl.
Table 1. Bone Mineral Density measures of total body, tibia,
trochanter and lumbar vertebrae 2-4 of studied mice (in mg/cm2).
No significant differences between groups were found (p>0.05).
osteoblast activity both directly and indirectly via
growth factors and cytokines [16,17]. The action of tri-
iodotyronine on osteoclastic bone resorption has been
suggested to be mediated predominantly by osteoblast-
derived osteotrophic cytokines such as IL-1, IL-6, IL-
8 and Tumour Necrosis Factor α [16,18]. Data from
the studies on osteoblastic bone marrow stromal cells
and osteoblast cell lines have reported that triiodotyro-
nine stimulates IL-6 expression and augments IL-1-
induced stimulation of IL-6 production [19,20].
IL-6 has been shown to be involved in the patho-
genesis of several bone diseases characterized by a
negative balance between bone resorption and forma-
tion. We have found lately unexpectedly increased
osteocalcin serum concentration in response to elevat-
ed bone resorption in IL6KO mice in experimental
thyrotoxicosis [13]. This finding suggest that IL-6
inhibits osteocalcin production and probably generally
bone formation in hyperthyroidism in mice. There are
no data in literature on the role of IL-6 in bone
turnover in hyperthyrosis. Our present study has
shown that both bone formation and resorption mark-
ers are decreased in hypothyroidism both in WT and
IL6KO. There were no differences between WT and
IL6KO hypothyroid mice as to BMD and TRACP 5b,
reflecting resorption rate as well as to osteocalcin, as
bone formation marker. Diminished indicators of bone
turnover in both IL6KO and WT mice may serve as an
indirect confirmation of efficacy of hypothyroidism.
Decreased bone metabolism markers were found in
hypothyroid patients [21]. Comparable levels of
TRACP 5b in IL6KO and WT mice may suggest that
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Fig. 3. The individual and median (–)
TRACP 5b serum levels of hypothy-
roid and control WT mice as well as
hypothyroid and control IL6KO mice.
Fig. 4. The individual and median (–)
osteocalcin serum levels of hypothy-
roid and control WT mice as well as
hypothyroid and control IL6KO mice.
IL-6 does not play an important role in the induction of
bone resorption in normal and hypothyroid mice, as far
as TRACP 5b molecules has been considered a useful
marker of bone resorption rate [22,23]. IL-6 was sug-
gested to be not a powerful bone-resorping factor in its
own right, but a molecule capable to enhance the
effects of other factors on bone resorption, such as NF-
kappa B ligand (RANK-L) [24]. Moreover, in culture
IL-6 was found to stimulate osteoclast formation and
bone resorption of mouse calvaria only slightly in
comparison to IL-1 [25]. Also in hyperthyroid patients
the increase in the levels of serum IL-6 was not relat-
ed directly with bone resorption seen in hyperthy-
roidism [26]. Experimentally induced increase in bone
resorption leading to bone loss is in general accompa-
nied with elevated bone formation, probably as an
attempt of the organism to maintain the bone balance
[27]. In the previous study in thyrotoxic IL-6 lacking
mice we observed greatly higher elevation of osteocal-
cin, suggesting a crucial role of this cytokine in inhibi-
tion of bone formation. Osteocalcin is an osteoblast
product that constitutes the most abundant noncollage-
nous protein present in bone and its serum levels close-
ly correlate with histomorphometric parameters of
bone formation [28]. In the present study lack of dif-
ference in serum osteocalcin as well as TRACP 5b in
hypothyroid WT and IL6KO mice suggest that IL-6 is
not crucial for the maintenance of the balance between
bone resorption and formation in hypothyroidism in
mice. It seems that IL-6 is in general an important
osteotropic factor in the state of increased bone
turnover and has minor role in physiological bone
remodeling and during processes associated with
inhibited bone turnover.   
To sum up, the results of the present study suggest
that IL-6 does not play an important role in bone
turnover in both euthyroid and hypothyroid mice.
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